Form 8-K - Current report:
SEC Accession No. 0001601830-24-000245
Filing Date
2024-12-17
Accepted
2024-12-17 17:06:27
Documents
16
Period of Report
2024-12-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rxrx-20241217.htm   iXBRL 8-K 23667
2 EX-5.1 exhibit51-rxrxxopiniontemp.htm EX-5.1 11819
7 image_1.jpg GRAPHIC 70458
  Complete submission text file 0001601830-24-000245.txt   268691

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rxrx-20241217.xsd EX-101.SCH 2042
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rxrx-20241217_def.xml EX-101.DEF 2843
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rxrx-20241217_lab.xml EX-101.LAB 23477
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rxrx-20241217_pre.xml EX-101.PRE 14135
18 EXTRACTED XBRL INSTANCE DOCUMENT rxrx-20241217_htm.xml XML 2746
Mailing Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101
Business Address 41S RIO GRANDE STREET SALT LAKE CITY UT 84101 (385) 269-0203
RECURSION PHARMACEUTICALS, INC. (Filer) CIK: 0001601830 (see all company filings)

EIN.: 464099738 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40323 | Film No.: 241556594
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)